First-to-market Pfizer expects a whopping $15B from its COVID-19 shot in 2021 States 'need more supply' of COVID-19 vaccine amid push to grant more shots Amid supply snafu, new data show AstraZeneca's COVID-19 shot is more effective with doses 12 weeks apart Ellume nets $232M government contract to produce COVID-19 home tests in U.S. HCA beat Wall Street expectations with $3.8B profit in year marked by roller coaster volumes, pandemic costs COVID-19 tracker: Moderna aims to fit more doses into shot vials UPDATED Coronavirus tracker: Biden admin to begin direct vaccine shipments to pharmacies CDMO Catalent trumpets biologics windfall courtesy of COVID-19 Pharma PR in a pandemic? Speed, clarity and accuracy count during unintentional stress test Featured Story | By Eric Sagonowsky More and more COVID-19 vaccines are nearing the market, but mRNA shots from Pfizer and Moderna are still working off a head start in the global rollout. Now, Pfizer has revealed just what that head start could be worth this year. read more |
| |
|---|
|
| | Webinar: The Benefits of Pharmacist-Led Clinical Trials Tuesday, February 23, 2021 | 1pm ET / 10am PT This webinar will focus on how a pharmacist-led clinical trial model impacts the six key areas most relevant to clinical trials in today’s COVID and Decentralized Clinical Trial environment: regulations, recruiting, diversity, clinical outcomes, data integrity, and clinical supply chain. Register Now. |
Top Stories By Robert King Several states told a congressional panel the have the capacity to deliver more COVID-19 doses than they are getting from the federal government. read more By Eric Sagonowsky While supply constraints have hung over the rollout of the AstraZeneca COVID-19 vaccine in Europe, last week, the company's CEO Pascal Soriot offered one way that officials could make the most out of available doses. And now more data support that approach—in fact, it might even be better. read more By Conor Hale Australian COVID-19 diagnostic maker Ellume has secured a $231.8 million contract from the Biden administration to establish its first production facility in the U.S., and deliver 8.5 million of its at-home tests. read more By Tina Reed The last year has been a roller coaster for hospitals across the country when it came to skyrocketing costs and fluctuating patient volumes. But for HCA Healthcare, it was a good year—financially speaking—with the Nashville, Tennessee-based hospital giant posting an uptick in profits for both the fourth quarter and the year. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale Moderna wants to fit more doses into its vaccine vials. Catalent's biologics revenue soared in the second quarter, thanks to a slew of COVID manufacturing projects. Ellume nabbed a $232 government contract to produce at-home COVID tests in the U.S. Plus, the CDC is ramping up efforts to track virus variants. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner Buoyed by production contracts with major COVID vaccine players Moderna, Johnson & Johnson and AstraZeneca, Catalent saw its biologics revenues hit $403.9 million in the second quarter its 2021 fiscal year. That's a whopping 76% increase in constant currencies over the same quarter last year. read more By Beth Snyder Bulik The COVID-19 pandemic has put pharma and healthcare public relations to the test, challenging communications teams in ways they couldn’t have anticipated. Now, after almost a year of racing to place accurate and clear messages in the market, Evoke Kyne—like many others—is emerging from the gauntlet with new hires and new business wins. read more |
